---
document_datetime: 2023-09-21 18:32:23
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/budesonideformoterol-teva-pharma-bv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: budesonideformoterol-teva-pharma-bv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3089065
conversion_datetime: 2025-12-23 05:17:41.043119
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Budesonide/Formoterol Teva Pharma B.V.

<!-- image -->

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IB/0004/G            | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation product | 17/09/2015                          |                                                | SmPC, Annex II, Labelling and PL |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

Medicinal product no longer authorised

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0002/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/07/2015   | n/a           |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|
| II/0001/G   | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal product | 26/03/2015   | n/a no longer |